All Stories

  1. Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications

    Article • Current Issues in Molecular Biology, July 2024, MDPI AG

    Dr Eleftheria Hatzimichael

  2. Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy

    Article • Annals of Hematology, June 2024, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  3. Imaging Flow Cytometry: Development, Present Applications, and Future Challenges

    Article • Methods and Protocols, March 2024, MDPI AG

    Dr Eleftheria Hatzimichael

  4. Expression Patterns of GATA3 in Classical Hodgkin Lymphoma: A Clinico-Pathological Study

    Article • Diseases, February 2024, MDPI AG

    Dr Eleftheria Hatzimichael

  5. Imaging Flow Cytometry: Development, Present Applications and Future Challenges

    Article • January 2024, MDPI AG

    Dr Eleftheria Hatzimichael

  6. The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1

    Article • Diseases, November 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  7. A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

    Article • Blood, November 2023, American Society of Hematology

    Dr Eleftheria Hatzimichael

  8. A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

    Article • Blood, November 2023, American Society of Hematology

    Dr Eleftheria Hatzimichael

  9. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    Article • EClinicalMedicine, November 2023, Elsevier

    Dr Eleftheria Hatzimichael

  10. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?

    Article • HemaSphere, November 2023, Wiley

    Dr Eleftheria Hatzimichael

  11. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?

    Article • Leukemia, October 2023, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  12. The Role of Non-Coding RNAs in Myelodysplastic Neoplasms

    Article • Cancers, September 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  13. The Role of Non-Coding RNAs in Myelodysplastic Neoplasms

    Article • August 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  14. Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report

    Article • Cureus, July 2023, Springer Science + Business Media

    Stelios Tigas, Dr Eleftheria Hatzimichael

  15. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications

    Article • Biology, June 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  16. Unravelling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications

    Article • May 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  17. Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis

    Article • Diseases, March 2023, MDPI AG

    Dr Eleftheria Hatzimichael

  18. The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms

    Article • American Journal of Hematology, March 2023, Wiley

    Dr Eleftheria Hatzimichael

  19. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries

    Article • Leukemia, January 2023, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  20. Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews

    Article • Critical Reviews in Oncology/Hematology, December 2022, Elsevier

    Dr Eleftheria Hatzimichael

  21. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

    Article • Blood, November 2022, American Society of Hematology

    Dr Eleftheria Hatzimichael

  22. Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

    Article • Blood, November 2022, American Society of Hematology

    Dr Eleftheria Hatzimichael

  23. INCIDENCE AND RISK FACTORS FOR CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA

    Article • Hematological Oncology, October 2022, Wiley

    Dr Eleftheria Hatzimichael

  24. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome

    Article • Scientific Reports, October 2022, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  25. Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis

    Article • Diseases, October 2022, MDPI AG

    Dr Eleftheria Hatzimichael

  26. Autophagy and cellular senescence in classical Hodgkin lymphoma

    Article • Pathology - Research and Practice, August 2022, Elsevier

    Dr Eleftheria Hatzimichael

  27. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia

    Article • Diseases, June 2022, MDPI AG

    Dr Eleftheria Hatzimichael

  28. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

    Article • In Vivo, January 2022, International Institute of Anticancer Research

    Dr Eleftheria Hatzimichael

  29. Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

    Article • Blood, November 2021, American Society of Hematology

    Dr Eleftheria Hatzimichael

  30. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

    Article • Blood, November 2021, American Society of Hematology

    Dr Eleftheria Hatzimichael

  31. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome

    Article • Pathology - Research and Practice, September 2021, Elsevier

    Dr Eleftheria Hatzimichael

  32. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis

    Article • Leukemia Research, August 2021, Elsevier

    Dr Eleftheria Hatzimichael

  33. Leishmaniasis mimicking multiple myeloma

    Article • International Journal of Laboratory Hematology, July 2021, Wiley

    Dr Eleftheria Hatzimichael

  34. Novel Therapeutic Advances in β-Thalassemia

    Article • Biology, June 2021, MDPI AG

    Dr Eleftheria Hatzimichael

  35. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

    Article • The Oncologist, June 2021, Oxford University Press (OUP)

    Dr Eleftheria Hatzimichael

  36. Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature

    Article • European Medical Journal, April 2021, European Medical Group

    Dr Eleftheria Hatzimichael

  37. Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas

    Article • Hematological Oncology, March 2021, Wiley

    Dr Eleftheria Hatzimichael

  38. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

    Article • Blood Cancer Journal, February 2021, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  39. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

    Article • Annals of Hematology, February 2021, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  40. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database

    Article • Leukemia Research, January 2021, Elsevier

    Dr Eleftheria Hatzimichael

  41. Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature

    Article • In Vivo, January 2021, International Institute of Anticancer Research

    Dr Eleftheria Hatzimichael

  42. Hyponatremia in Patients with Hematologic Diseases

    Article • Journal of Clinical Medicine, November 2020, MDPI AG

    Dr Eleftheria Hatzimichael

  43. Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child: Diagnostic and Clinical Implications

    Article • Journal of Pediatric Hematology/Oncology, October 2020, Wolters Kluwer Health

    Dr Eleftheria Hatzimichael

  44. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Article • Leukemia, September 2020, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  45. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas

    Article • Annals of Nuclear Medicine, September 2020, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  46. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

    Article • British Journal of Haematology, August 2020, Wiley

    Dr Eleftheria Hatzimichael

  47. Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study

    Article • eJHaem, July 2020, Wiley

    Dr Eleftheria Hatzimichael

  48. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes

    Article • Hematological Oncology, June 2020, Wiley

    Dr Eleftheria Hatzimichael

  49. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2020, Elsevier

    Dr Eleftheria Hatzimichael

  50. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective ...

    Article • Therapeutic Advances in Hematology, January 2020, SAGE Publications

    Dr Eleftheria Hatzimichael

  51. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group

    Article • Journal of Geriatric Oncology, January 2020, Elsevier

    Dr Eleftheria Hatzimichael

  52. A Novel εγδβ-Thalassemia Deletion Associated with Severe Anemia at Birth and a β-Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family

    Article • Hemoglobin, December 2019, Taylor & Francis

    Dr Eleftheria Hatzimichael

  53. Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Regist...

    Article • Blood, November 2019, American Society of Hematology

    Dr Eleftheria Hatzimichael

  54. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

    Article • Blood, November 2019, American Society of Hematology

    Dr Eleftheria Hatzimichael

  55. The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

    Article • Blood, November 2019, American Society of Hematology

    Dr Eleftheria Hatzimichael

  56. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry

    Article • Cancer Medicine, March 2019, Wiley

    Dr Eleftheria Hatzimichael

  57. Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

    Article • Blood, November 2018, American Society of Hematology

    Dr Eleftheria Hatzimichael

  58. Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system

    Article • Leukemia & Lymphoma, November 2018, Taylor & Francis

    Vasiliki Pappa, Stamatis Karakatsanis, Dr Eleftheria Hatzimichael

  59. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group

    Article • Hematological Oncology, September 2018, Wiley

    Vasiliki Pappa, Dr Eleftheria Hatzimichael

  60. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group

    Article • Leukemia Research, August 2018, Elsevier

    Dr Eleftheria Hatzimichael

  61. Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

    Article • Annals of Hematology, June 2018, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  62. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

    Article • Hematological Oncology, June 2018, Wiley

    Vasiliki Pappa, Dr Maria K Angelopoulou, Dr Eleftheria Hatzimichael

  63. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group

    Article • American Journal of Hematology, May 2018, Wiley

    Vasiliki Pappa, Dr Eleftheria Hatzimichael

  64. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

    Article • Annals of Hematology, May 2018, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  65. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

    Article • European Journal Of Haematology, September 2017, Wiley

    Dr Marie-Christine Kyrtsonis, Dr Eleftheria Hatzimichael

  66. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation

    Article • Cancer Letters, August 2017, Elsevier

    Dr Eleftheria Hatzimichael

  67. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences

    Article • Journal of Clinical Lipidology, July 2017, Elsevier

    Dr Eleftheria Hatzimichael

  68. Lenalidomide Induces Responses in Patients with MDS-DEL(5)Q Alone, or with One Additional Abnormality, Irrespective of Who Classification and Prognostic Categorization

    Article • Leukemia Research, April 2017, Elsevier

    Dr Eleftheria Hatzimichael

  69. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry

    Article • Tumor Biology, March 2017, SAGE Publications

    Dr Eleftheria Hatzimichael

  70. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

    Article • Hematological Oncology, February 2017, Wiley

    Dr Marie-Christine Kyrtsonis, Dr Maria K Angelopoulou, Dimitrios Grenzelias, Vasiliki Pappa, Dr Eleftheria Hatzimichael

  71. Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis

    Article • Advances in Hematology, January 2017, Hindawi Publishing Corporation

    Dr Eleftheria Hatzimichael

  72. Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review

    Article • Case Reports in Hematology, January 2017, Hindawi Publishing Corporation

    Dr Eleftheria Hatzimichael

  73. 2017 Clinical trials update in new treatments of β-thalassemia

    Article • American Journal of Hematology, October 2016, Wiley

    Dr Eleftheria Hatzimichael

  74. Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms

    Article • Clinical and Experimental Medicine, September 2016, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  75. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

    Article • Molecular and Clinical Oncology, April 2016, Spandidos Publications

    Dr Eleftheria Hatzimichael

  76. Megaloblastic anemia presenting with skin hyperpigmentation

    Article • International Journal of Hematology, March 2016, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  77. Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus–copositive lymphoproliferations

    Article • Human Pathology, October 2015, Elsevier

    Dr Eleftheria Hatzimichael

  78. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs

    Article • Proceedings of the National Academy of Sciences, February 2015, Proceedings of the National Academy of Sciences

    Dr Eleftheria Hatzimichael

  79. Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic Activity

    Article • ACS Chemical Biology, December 2014, American Chemical Society (ACS)

    Ms Maria V Chatziathanasiadou, Dr Eleftheria Hatzimichael

  80. Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies

    Article • Clinical Lymphoma Myeloma & Leukemia, December 2014, Elsevier

    Dr Eleftheria Hatzimichael

  81. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist

    Article • Cellular and Molecular Life Sciences, August 2014, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  82. Profile of pacritinib and its potential in the treatment of hematologic disorders

    Article • Journal of Blood Medicine, August 2014, Dove Medical Press

    Dr Eleftheria Hatzimichael, Dr Evangelos Tsolas

  83. A blood test to identify when melanoma metastasizes: a reality for melanoma management?

    Article • Melanoma Management, August 2014, Future Medicine

    Dr Eleftheria Hatzimichael

  84. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis

    Article • Expert Review of Molecular Diagnostics, June 2014, Taylor & Francis

    Dr Eleftheria Hatzimichael

  85. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

    Article • Leukemia, March 2014, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  86. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome

    Article • Biology Direct, February 2014, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  87. Metronomic chemotherapy beyond misconceptions

    Article • Haematologica, November 2013, Ferrata Storti Foundation (Haematologica)

    Dr Eleftheria Hatzimichael

  88. Polycomb group proteins and MYC: the cancer connection

    Article • Cellular and Molecular Life Sciences, July 2013, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  89. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group

    Article • Annals of Hematology, July 2013, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  90. Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia

    Article • British Journal of Haematology, July 2013, Wiley

    Dr Eleftheria Hatzimichael

  91. Revisiting bleomycin from pathophysiology to safe clinical use

    Article • Critical Reviews in Oncology/Hematology, July 2013, Elsevier

    Dr Eleftheria Hatzimichael

  92. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma

    Article • Journal of Investigative Dermatology, May 2013, Elsevier

    Dr Eleftheria Hatzimichael

  93. Cancer Epigenetics: New Therapies and New Challenges

    Article • Journal of Drug Delivery, February 2013, Wiley

    Dr Eleftheria Hatzimichael

  94. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma

    Article • Cell Death and Disease, January 2013, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  95. Clinical trial design in biosimilar drug development

    Article • Investigational New Drugs, November 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  96. Non‐coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome

    Article • International Journal of Cancer, October 2012, Wiley

    Dr Eleftheria Hatzimichael

  97. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma

    Article • British Journal of Cancer, September 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  98. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis

    Article • Cellular and Molecular Life Sciences, July 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  99. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

    Article • Cell Death and Disease, July 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  100. Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

    Article • European Journal Of Haematology, June 2012, Wiley

    Dr Eleftheria Hatzimichael

  101. NT5E CpG island methylation is a favourable breast cancer biomarker

    Article • British Journal of Cancer, May 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  102. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients

    Article • Supportive Care in Cancer, April 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  103. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity

    Article • British Journal of Cancer, March 2012, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  104. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications

    Article • Leukemia & Lymphoma, March 2012, Taylor & Francis

    Dr Eleftheria Hatzimichael

  105. Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer

    Article • Oncotarget, January 2012, Impact Journals, LLC

    Dr Eleftheria Hatzimichael

  106. Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches

    Article • Molecules, May 2011, MDPI AG

    Dr Eleftheria Hatzimichael

  107. MEG3 imprinted gene contribution in tumorigenesis

    Article • International Journal of Cancer, May 2011, Wiley

    Dr Eleftheria Hatzimichael

  108. Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Eleftheria Hatzimichael

  109. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions

    Article • Annals of Hematology, February 2011, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  110. Study of specific genetic and epigenetic variables in multiple myeloma

    Article • Leukemia & Lymphoma, November 2010, Taylor & Francis

    Dr Eleftheria Hatzimichael

  111. Cytokine and Adhesion Molecule Expression Evolves Between the Neutrophilic and Lymphocytic Phases of Viral Meningitis

    Article • Journal of Interferon & Cytokine Research, September 2010, Mary Ann Liebert Inc

    Dr Eleftheria Hatzimichael

  112. Hematopoietic stem cell transplantation

    Article • Stem Cells and Cloning Advances and Applications, August 2010, Taylor & Francis

    Dr Eleftheria Hatzimichael

  113. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma

    Article • British Journal of Cancer, June 2010, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  114. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes

    Article • Leukemia Research, February 2010, Elsevier

    Dr Eleftheria Hatzimichael

  115. Serum Adipocytokine and Vascular Inflammation Marker Levels in Beta-Thalassaemia Major Patients

    Article • Acta Haematologica, January 2010, Karger Publishers

    Dr Eleftheria Hatzimichael

  116. The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia

    Article • European Journal Of Haematology, December 2009, Wiley

    Dr Eleftheria Hatzimichael

  117. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

    Article • Haematologica, September 2009, Ferrata Storti Foundation (Haematologica)

    Dr Eleftheria Hatzimichael

  118. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia

    Article • Leukemia Research, September 2009, Elsevier

    Dr Eleftheria Hatzimichael

  119. von Hippel–Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease

    Article • Clinical Lymphoma & Myeloma, June 2009, Elsevier

    Dr Eleftheria Hatzimichael

  120. P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes

    Article • Leukemia Research, May 2009, Elsevier

    Dr Eleftheria Hatzimichael

  121. P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group

    Article • Leukemia Research, May 2009, Elsevier

    Dr Eleftheria Hatzimichael

  122. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease

    Article • Annals of Oncology, April 2009, Elsevier

    Dr Eleftheria Hatzimichael

  123. Methylation Changes in Neoplasia

    Article • September 2008, Taylor & Francis

    Dr Eleftheria Hatzimichael

  124. Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma

    Article • Clinical Lymphoma & Myeloma, June 2008, Elsevier

    Dr Eleftheria Hatzimichael

  125. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms

    Article • British Journal of Haematology, March 2008, Wiley

    Dr Eleftheria Hatzimichael

  126. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes

    Article • Leukemia, December 2007, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  127. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases

    Article • Hematology, December 2007, Taylor & Francis

    Dr Eleftheria Hatzimichael

  128. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient

    Article • Leukemia Research, January 2007, Elsevier

    Dr Eleftheria Hatzimichael

  129. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support

    Article • International Journal of Laboratory Hematology, December 2006, Wiley

    Dr Eleftheria Hatzimichael

  130. The genomics of new drugs in sickle cell disease

    Article • Pharmacogenomics, September 2006, Future Medicine

    Dr Eleftheria Hatzimichael

  131. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma

    Article • Annals of Oncology, March 2006, Elsevier

    Dr Eleftheria Hatzimichael

  132. C-Reactive Protein and Vascular Cell Adhesion Molecule-1 as Markers of Severity in Sickle Cell Disease

    Article • Archives of Internal Medicine, February 2006, American Medical Association (AMA)

    Dr Eleftheria Hatzimichael

  133. Host Pharmacogenetics in the Treatment of HIV and Cancer

    Article • Current Drug Safety, January 2006, Bentham Science Publishers

    Dr Eleftheria Hatzimichael

  134. The Rationale and Development of New Drugs to Treat HIV Infection

    Article • Medicinal Chemistry, November 2005, Bentham Science Publishers

    Dr Eleftheria Hatzimichael

  135. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Rα) as a predictor of outcome in brucellosis

    Article • Journal of Infection, October 2005, Elsevier

    Dr Eleftheria Hatzimichael

  136. Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases

    Article • British Journal of Haematology, August 2005, Wiley

    Dr Eleftheria Hatzimichael

  137. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients

    Article • Multiple Sclerosis Journal, June 2005, SAGE Publications

    Dr Eleftheria Hatzimichael

  138. Treatment of β-Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules

    Article • Acta Haematologica, January 2004, Karger Publishers

    Dr Eleftheria Hatzimichael

  139. Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient

    Article • Annals of Hematology, August 2001, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  140. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone

    Article • European Journal Of Haematology, July 2001, Wiley

    Dr Eleftheria Hatzimichael

  141. Investigation for the presence of anti‐erythropoietin antibodies in patients with myelodysplastic syndromes

    Article • European Journal Of Haematology, January 2001, Wiley

    Dr Eleftheria Hatzimichael

  142. Serum levels of IL‐6 and its soluble receptor (sIL‐6R) in Waldenström's macroglobulinemia

    Article • European Journal Of Haematology, January 2001, Wiley

    Dr Eleftheria Hatzimichael

  143. The role of cytokines in sickle cell disease

    Article • Annals of Hematology, August 2000, Springer Science + Business Media

    Dr Eleftheria Hatzimichael

  144. Prolonged interferon‐alpha‐2b treatment of hairy cell leukemia patients

    Article • European Journal Of Haematology, May 2000, Wiley

    Dr Eleftheria Hatzimichael

  145. Alpha-2-Macroglobulin and Interleukin-6 Levels in Steady-State Sickle Cell Disease Patients

    Article • Acta Haematologica, January 2000, Karger Publishers

    Dr Eleftheria Hatzimichael

  146. Serum beta‐2‐microglobulin, TNF‐α and interleukins in myeloproliferative disorders

    Article • European Journal Of Haematology, July 1999, Wiley

    Dr Eleftheria Hatzimichael

  147. Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia

    Article • European Journal of Internal Medicine, May 1999, Elsevier

    Dr Eleftheria Hatzimichael

  148. A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival

    Article • Acta Haematologica, January 1999, Karger Publishers

    Dr Eleftheria Hatzimichael